Please amend the above-identified application as follows:

In the Specification

At page 25, Table 6, 3rd ~~row~~ of data (reciting "in 100 ++ 10/12 83 <0.0001"), delete "in" and insert therefor --iv--.

In the Claims

Please cancel Claims 1-3, 5-7, 9-26, 28-38, 40-43, 52-61, 65-66 73 and 75-77. Add Claims 81-89. Amend Claims 62, 63, 64, 68, 74 and 78 as follows:

~~62~~. (Amended) A composition comprising a DNA transcription unit and a physiologically acceptable carrier, wherein the DNA transcription unit comprises DNA encoding an antigen of [an] human immunodeficiency virus operatively linked to a promoter region, and wherein the DNA transcription unit comprises a construct selected from the group consisting of: pCMV/HIV-1-NL4-3.dpol, pCMV/HIV-1-HXB-2.env, pCMV/HIV-NL4-3.env, JW4303/HIV-1-HXB-2.sgp120, and JW4303/HIV-1-HXB-2.sgp140.

~~63~~. (Amended) The composition of Claim ~~62~~, further comprising one or more additional DNA transcription units, each DNA transcription unit comprising DNA encoding an antigen of a different subgroup of the human immunodeficiency virus.

3 ~~64~~. (Amended) The composition of Claim ~~62~~ 1, further comprising one or more additional DNA transcription units, each DNA transcription unit comprising DNA encoding an antigen of a different subtype of the human immunodeficiency virus.

F1

4 ~~68~~. (Amended) A composition comprising more than one DNA transcription unit and a physiologically acceptable carrier, wherein each DNA transcription unit comprises DNA encoding an antigen of human immunodeficiency virus operatively linked to a promoter region, and wherein at least one of the DNA transcription units comprises a construct selected from the group consisting of: pCMV/HIV-1-NL4-3.dpol, pCMV/HIV-1-HXB-2.env, pCMV/HIV-NL4-3.env, JW4303/HIV-1-HXB-2.sgp120, and JW4303/HIV-1-HXB-2.sgp140.

F2

1 ~~74~~. (Amended) The composition of Claim [73] ~~68~~ 4, wherein the DNA transcription unit comprises DNA encoding eight of the nine human immunodeficiency virus proteins.

F3

8 ~~78~~. (Amended) A plasmid vector comprising a promoter region operably linked to a nucleotide sequence encoding an antigen of human immunodeficiency virus, wherein said vector comprises a construct selected from the group consisting of: pCMV/HIV-1-NL4-3.dpol, pCMV/HIV-1-HXB-2.env, pCMV/HIV-NL4-3.env, JW4303/HIV-1-HXB-2.sgp120, and JW4303/HIV-1-HXB-2.sgp140, and wherein said antigen of human immunodeficiency virus is expressed in a cell of a mammal inoculated with said plasmid vector.

F4

Please add the following claims:

81. The method of Claim 44, wherein the promoter region of the DNA transcription unit is not of retroviral origin.

82. The method of Claim 44, wherein the promoter region of the DNA transcription unit is of retroviral origin.

BOARD DECISION

83. The method of Claim 44, wherein the DNA transcription unit is administered to a mammal through a route of administration selected from the group consisting of: intravenous, intramuscular, intraperitoneal, intradermal and subcutaneous.

84. The method of Claim 44, wherein the DNA transcription unit is administered to a mammal by contacting the DNA transcription unit with a mucosal surface of the mammal.

P5

85. The method of Claim 84, wherein the mucosal surface is a respiratory mucosal surface.

86. The method of Claim 85, wherein the respiratory mucosal surface is a nasal mucosal surface.

87. The method of Claim 85, wherein the respiratory mucosal surface is a tracheal mucosal surface.

88. The method of Claim 44, wherein the DNA transcription unit is microsphere-encapsulated.

F